June 2016

New Product - Akynzeo

Akynzeo (netupitant/palonosetron (as hydrochloride)) contains a selective high affinity antagonist of human substance P/neurokinin 1 (NK₁) receptors (netupitant) and a selective serotonin subtype 3 (5‑HT₃ ) receptor antagonist with a strong binding affinity for this receptor (palonosetron). Akynzeo is indicated in adult patients for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy and also for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. Akynzeo is available as a hard gelatin capsule containing netupitant 300 mg (3 100 mg immediate release tablets) and palonosetron (Hcl) 500 mcg (1 soft gel cap) in blister packs of 1’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au